Risk groups stratification of patients with gastrointestinal stromal tumors: defining the feasibility of adjuvant therapy and its duration
Abstract
Experience of adjuvant therapy of patients with gastrointestinal stromal tumors (GISTs) has demonstrated high efficacy allowing almost two-fold increase of patients’ recurrence-free survival. Currently, low risk patients after radical surgical treatment are closely followed up; moderate risk GIST patients are recommended adjuvant therapy with imatinib for 1 year whereas those of high risk – for 3 years. This article presents the review of significant predictors, analysis of which shall let a clinical oncologist stratify patients into risk groups most precisely thus improving the efficacy of target therapy.
About the Authors
A. G. Kornilova
МУЗ ПГКб; ФУВ ГбУЗ МО МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
L. M. Kogoniya
ГбУЗ МО МОНИКИ
Russian Federation
Russian Federation
V. G. Mos’kin
ГбУЗ МО МОНИКИ; ГбУЗ МО
Russian Federation
Russian Federation
S. V. Mordanov
Ростовского гос. мед. университета
Russian Federation
Russian Federation
O. S. Oksenyuk
ГбОУ ВПО РостГМУ Минздрава России
Russian Federation
Russian Federation
References
1. Nikulin M.P. Gastrointestinal stromal tumors (GIST). Epidemiology, diagnosis, modern approaches to treatment / Nikulin I.P., Stilidi I.S. // Contemporary Oncology. Extra issue. 2007. P. 3-50.
2. Snigur P.V. Stromal tumors of the duodenum / P.V. Snigur, O.A. Anurova / / Surgery. 2003. №11. p. 46-48.
3. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas / К. Antman [et al.] // J Clin Oncol. – 1993. № 11(7). Р. 1276-1285.
4. Benjamin R.S. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results / R.S. Benjamin, С. Rankin, С. Fletcher //. Proc Am Soc Clin Oncol. 2003. - №22. Р. 814.
5. Blackstein M.E. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001/ М. е. Blackstein // GI ASCO. – 2010.- №6.
6. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 / M. Sarlomo-Rikala [et al.] // Mod Pathol. l998.- № 11(8).P. 728-734.
7. Corless C.L. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib / C.L. Corless, A. Schroeder, D.J. Griffith // Clin. Oncol. – 2005. № 23. Р. 5357–5364.
8. Daum O. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors / O. Daum, P. Grossmann, T. Vanecek // Ann. Diagn. Pathol. – 2007. № 11. – Р. 27–33.
9. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis /J.S.Gold [et al.] // Lancet Oncol. 2009. №10(11). P. 1045-52.
10. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. – 2010.Р. 147153.
11. ESMO Update Clinical Practice Guidelines. Ann of Oncol. 2012.№23.Supplement 7.
12. European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediateor high-risk of relapse. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors / A.D. Van den Abbelle [et al.] // Proc Am Soc Clin Oncol. – 2001.№ 20.P. 362.
13. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up / M. Miettinen [et al.]// Am. J Surg. Pathol. 2006.№30.P. 477–489.
14. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management / I. Pidhorecky [et al.] // Ann Surg Oncol. – 2000.-№ 7(9).P.705-712.
15. Gain-function mutations of c-kit in human gastrointestinal stromal tumors/ S. Hirota [et al.] //Science. – 1998.№279.P. 577-580.
16. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal / L.G. Kindblom [et al.] // Am J Pathol. – 1998.№152(5).P.1259-69.
17. High incidence of microscopic gastrointestinal stromal tumors in the stomach / K. Kawanowa [et al.] // Human Pathol. 2006. - №37(12). P. 1527-1535.
18. Guillou L. Prognostic factors in soft tissue sarcoma in the adult/ L. Guillou, J.M.Coindre // Ann Pathol. 1997. №17(6). P. 375-377.
19. Hassan I. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis / I. Hassan, Y.N. You., R. Shyyan // Ann Surg Oncol. 2008. №15(1).P. 52-59.
20. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor/ H. Joensuu H// Hum Pathol. – 2008.№ 39(10).P.1411-1419.
21. Lasota J. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours /J.Lasota, M.Miettinen// Histopathology. – 2008. -№ 4.P.4–16.
22. Martin J. Deletions affecting codons 557558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)/ J.Martin, J. Poveda, A.J. Llombart-Bosch //Clin. Oncol. – 2005.№23.P. 6190– 6198.
23. Mazur M.T. Gastric stromal tumors: Reappraisal of histogenesis/ M.T. Mazur, H.B.Clark // Am J Surg. Pathol. – 1983.-№7.P.507-519.
24. Miettinen M. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review / M.Miettinen, W.El-Rifai // Hum Pathol. – 2002.№33.P. 478–483.
25. Miettinen M. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases / M. Miettinen, J.F. Fetsch, L.H. Sobin // Am. J. Surg. Pathol. 2006.№30.P. 90–96.
26. Miettinen M. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis / M. Miettinen, J. Lasota // Virchows Arch.-2001.-№438(1).-P.1-12.
27. Miettinen M. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics / M. Miettinen, J. Lasota // Pol. J. Pathol. – 2003.- №54.P.3–24.
28. Miettinen M. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis / M. Miettinen // Arch Pathol Lab Med. 2006.- №130.P.1466–1478.
29. Miettinen M. Gastrointestinal stromal tumors of the stomach—a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up / M. Miettinen, L.H. Sobin, J. Lasota // Am. J. Surg. Pathol. 2005.№29.P. 52–68.
30. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations /A. Agaimy [et al.] //Am J Surg Pathol. – 2007.№31(1).Р.113120.
31. Mudan S. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection / S. Mudan, K. Conlon, J.Woodruff // Canсer. – 2000.№ 88.P. 66-74.
32. One vs three years of adjuvant imatinib for operable GIST: a randomized trial / H. Joensuu [et al.] // JAMA. – 2012.№307(12). P.126572.
33. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study / M. Zalupski [et al.] //J Nat Cancer Inst. – 1991.№ 83(13).P. 926-932.
34. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging / E.H. Ng [et al.] // Ann Surg. – 1992.№215(1). P. 68-77.
35. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors / S. Singer [et al.] // J Clin Oncol. – 2002.№ 20(18).P. 38983905.
36. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors / В. Belev [et al.] //World J Gastroenterol. – 2013. № 19(4). Р. 523-527.
37. Rutkowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate / P. Rutkowski, Z. Nowecki, P. Nyckowski // J Surg Oncol. – 2006.- №93.P. 304–311.
Review
For citations:
Kornilova A.G., Kogoniya L.M., Mos’kin V.G., Mordanov S.V., Oksenyuk O.S. Risk groups stratification of patients with gastrointestinal stromal tumors: defining the feasibility of adjuvant therapy and its duration. Yakut Medical Journal. 2014;(3):12-16.
Views:
26
Email this article 